Leede Financial Forecasts TSE:MDP FY2025 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Analysts at Leede Financial increased their FY2025 earnings per share estimates for Medexus Pharmaceuticals in a note issued to investors on Monday, December 2nd. Leede Financial analyst D. Loe now anticipates that the company will post earnings of $0.20 per share for the year, up from their previous estimate of $0.19. Leede Financial currently has a “Speculative Buy” rating and a $8.25 price target on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

A number of other research firms also recently commented on MDP. Stifel Canada raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Monday, August 12th. Raymond James upgraded shares of Medexus Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the company from C$3.00 to C$4.00 in a research report on Wednesday, November 20th. Finally, Stifel Nicolaus upped their price target on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of C$5.25.

Medexus Pharmaceuticals Price Performance

Shares of TSE MDP opened at C$2.80 on Wednesday. The business has a fifty day moving average price of C$2.47 and a two-hundred day moving average price of C$2.25. The stock has a market capitalization of C$68.68 million, a PE ratio of 56.00 and a beta of 1.96. Medexus Pharmaceuticals has a fifty-two week low of C$1.44 and a fifty-two week high of C$3.16.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.